

Merck's own clinical studies found -44.6% (negative) efficacy for women previously exposed to HPV infections.

Table 17. Study 013: Applicant's analysis of efficacy against vaccine-relevant HPV types CIN 2/3 or worse among subjects who were PCR positive and seropositive for relevant HPV types at day 1. [From original BLA, study 013 CSR, Table 11-88, p. 636]

Endpoint	Gardasil™ N=2717				Placebo N=2725				Observed Efficacy	95% CI
	N (subgroup)	Number of cases	PY at risk	Incidence Rate per 100 person years at risk	N (subgroup)	Number of cases	PY at risk	Incidence Rate per 100 person years at risk		
HPV 6/11/16/18 CIN 2/3 or worse	156	31	278.9	11.1	137	19	247.1	7.7	-44.6%	<0.0, 8.5%

Translation: Gardasil increases the risk of cervical cancer by 44.6% in women who were exposed to HPV prior to receiving the vaccine.

STUDY: 34% OF CHILDREN AGES 2-10 HAVE HPV INFECTION DUE TO NON-SEXUAL TRANSMISSION (BIRTH CANAL, CASUAL CONTACT)

Original Study

Genital HPV in Children and Adolescents: Does Sexual Activity Make a Difference?

Flora Bacopoulou MD, IFEPAG, PhD^{1,*}, Petros Karakitsos MD, PhD², Christine Kottaridi PhD², Charikleia Stefanaki MD¹, Efthymios Deligeoroglou MD, PhD¹, Kalliopi Theodoridou MD, PhD¹, George P. Chrousos MD, MACP, MACE, FRCP (London)¹, Athanasios Michos MD, PhD³

¹Center for Adolescent Medicine and United Nations Educational, Scientific and Cultural Organization (UNESCO) Chair on Adolescent Health Care, First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece

²Department of Cytopathology, Attikon University Hospital, Athens, Greece

³Division of Infectious Diseases, First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece

48% of women ages 26-45 are infected, according to Merck's package inserts.

(24% have high-risk strain)

Journal of Pediatric & Adolescent Gynecology, 29(3):228-233, June 2016

Table 2

HPV Infection Characteristics in Vaginal or Cervical Samples of 95 Children and Adolescents

HPV Infection Characteristics	Sexually Active Adolescents	Not Sexually Active Adolescents	Prepubertal Children	Cumulative Number	P
Total population	n = 38	n = 28	n = 29	n = 95	
HPV infection	18 (47.4)	8 (28.6)	10 (34.5)	36 (37.9)	.27
Single infection	8 (21.1)	5 (17.9)	6 (20.7)	19 (20)	.94
Multiple infection	10 (26.3)	3 (10.7)	4 (13.8)	17 (17.9)	.21
Low-risk strain	4 (10.5)	2 (7.1)	5 (17.2)	11 (11.6)	.48
High-risk strain	18 (47.4)	8 (28.6)	7 (24.1)	33 (34.7)	.10

HPV, human papillomavirus



Data are presented as n (%).

CDC recommends Gardasil for women until age 45 with no testing to determine HPV status.

RESULTS : PRE VACCINATION PERIOD

During the 1989-2007 period, the incidence of invasive cervical cancer declined continuously in all countries with pap screening


Cervical Cancer (CIS), European Age-Standardised Incidence Rate:



These impressive advances are due to pap screening

Cervical cancer increase in Australia following vaccine introduction.

Australia Increase of incidence after << catch up vaccines (14-26 y in 2007, 21-33 in 2014) >>



Cervical cancer increase in United Kingdom following the start of the HPV vaccination program.

Figure 1 UK. In the vaccinated age group (20-24) the incidence of invasive cancer jumped up in 2011, (3 years after start of school vaccination campaign. (graphic from cancer Research UK)

Cervical Cancer (C53), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2015




Figure 2 Sweden. In Sweden breakpoint analysis : the incidence of invasive cancer climbed up from 2011, 2 years after vaccination campaign (graph published by Nordean 2019 05 29)

Cervical cancer increase in Sweden following vaccine the start of HPV vaccine campaign.





Figure 3. Norway. In the vaccinated age group (15-24) the 3 years smoothed incidence of invasive cancer climbed up from 2011, 2 years after vaccination campaign (graph published by Nordcan)

**Cervical
cancer
increase in
Norway
following the
beginning of
HPV vaccine
campaign.**

Incidence: Norway
Cervix uteri



Cervix uteri

Age Standardised Incidence Rate (World), age [0-85+]




Figure 4: Comparison of the trends of incidence of invasive cervical cancer during the first years of vaccination (2007-2012). The incidence of cervix cancer improved in France and worsened in countries with large vaccination uptake.